Leslie Khawli

Title(s)Professor Of Clinical Pathology
SchoolKeck School of Medicine of Usc
AddressHMR 2011 Zonal Ave
Health Sciences Campus
Los Angeles CA 90089-9092
Phone+1 323 442 3337
ORCID ORCID Icon0000-0002-7346-2818 Additional info
vCardDownload vCard
    Other Positions
    Title(s)Director of the Pathology Graduate Program


    Collapse Overview 
    Collapse Overview
    Dr. Leslie Khawli is a member of the faculty at the Keck School of Medicine of USC and currently the Director of the Pathology Graduate Program. Dr. Khawli holds a bachelor’s degree in biology from the American University of Beirut, Lebanon and a PhD in bioorganic chemistry from the University of Southern California, Los Angeles. After completing a NIH postdoctoral research fellowship in experimental nuclear medicine at Harvard Medical School in Boston, he joined the faculty at USC and has achieved the status of full professor. Dr. Khawli successfully made a transition to the biotechnology industry and joined Genentech/Roche in San Francisco to lead a wide range of research scientists in the practical application of his research and skills. After 8 years, he made a switch back to USC so he could translate his real-industrial drug development experience into an academic role.
    Dr. Khawli active research has been revolved around the interface of chemistry and biology, specifically in the design, characterization and delivery of antibody, ADC, fusion protein, and cell-based therapeutics. A major research focus is to increase the value of mechanistic pharmacology of targeted biotherapeutics and investigate the structural and functional properties affecting their pharmacokinetics, biodistribution and metabolism, while ensuring safety and efficacy. His laboratory works effectively with Dr. Alan Epstein and many other interdisciplinary teams at USC to support the preclinical development of biotherapeutics that translate to clinical applications. These joint collaborative efforts have been supported by research agencies, private foundations, and numerous pharmaceutical companies. Dr. Khawli research has been reported in more than 100 peer-reviewed publications as well as book chapters and review articles. His research discoveries have resulted in several US and international patents pertaining to the targeted delivery of biotherapeutics. He is an accomplished scientist in his field and has been actively participating in various biotechnology companies in the US and abroad as a scientific consultant.
    Dr. Khawli has had a long-standing commitment to various education and administrative programs aimed at mentoring and training graduate students and young researchers for careers in academia or biotech and pharma industry. He is also the recipient of numerous teaching, research and service awards.
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma. J Neurosurg. 2023 Dec 29; 1-9. Wang W, He H, Zheng L, Zeng S, Cho HY, Kouhi A, Khawli LA, Chen L, Stathopoulos A, Schönthal AH, Epstein AL, Chen TC. PMID: 38157532.
      View in: PubMed   Mentions: 1     Fields:    
    2. Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model. Sci Rep. 2021 07 23; 11(1):15077. Sta Maria NS, Khawli LA, Pachipulusu V, Lin SW, Zheng L, Cohrs D, Liu X, Hu P, Epstein AL, Jacobs RE. PMID: 34302002; PMCID: PMC8302724.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    3. Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives. Int J Mol Sci. 2021 Jun 16; 22(12). Kouhi A, Pachipulusu V, Kapenstein T, Hu P, Epstein AL, Khawli LA. PMID: 34208575; PMCID: PMC8235515.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    4. Advances in Immuno-PET for the Detection of Cancer and Assessment of Response to Therapy. Curr Med Chem. 2021; 28(4):647-672. Alauddin MM, Khawli LA. PMID: 32003655.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    5. Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations. Antibodies (Basel). 2020 Jun 10; 9(2). Boune S, Hu P, Epstein AL, Khawli LA. PMID: 32532067; PMCID: PMC7345016.
      View in: PubMed   Mentions: 35  
    6. A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models. Clin Cancer Res. 2020 07 15; 26(14):3694-3706. Zheng L, Ren L, Kouhi A, Khawli LA, Hu P, Kaslow HR, Epstein AL. PMID: 32273277.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    7. Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer. Oncotarget. 2019 Oct 22; 10(58):6234-6244. Boswell CA, Yadav DB, Mundo EE, Yu SF, Lacap JA, Fourie-O'Donohue A, Kozak KR, Ferl GZ, Zhang C, Ho J, Ulufatu S, Khawli LA, Lin K. PMID: 31692898; PMCID: PMC6817444.
      View in: PubMed   Mentions: 6     Fields:    
    8. Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma. Int J Mol Sci. 2017 Dec 20; 18(12). Zheng L, Hu P, Wolfe B, Gonsalves C, Ren L, Khawli LA, Kaslow HR, Epstein AL. PMID: 29261129; PMCID: PMC5751371.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    9. Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development. J Immunol Res. 2016; 2016:8141269. Lu Y, Khawli LA, Purushothama S, Theil FP, Partridge MA. PMID: 27642612; PMCID: PMC5011518.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    10. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. J Immunol Res. 2016; 2016:2342187. Smith A, Manoli H, Jaw S, Frutoz K, Epstein AL, Khawli LA, Theil FP. PMID: 27579329; PMCID: PMC4992793.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    11. Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models. Cancer Immunol Immunother. 2016 May; 65(5):511-23. Jang JK, Khawli LA, Canter DC, Hu P, Zhu TH, Wu BW, Angell TE, Li Z, Epstein AL. PMID: 26960932; PMCID: PMC4841721.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    12. Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. MAbs. 2016; 8(2):229-45. Tibbitts J, Canter D, Graff R, Smith A, Khawli LA. PMID: 26636901; PMCID: PMC4966629.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimals
    13. Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics. J Biol Chem. 2015 Dec 11; 290(50):29732-41. Bumbaca Yadav D, Sharma VK, Boswell CA, Hotzel I, Tesar D, Shang Y, Ying Y, Fischer SK, Grogan JL, Chiang EY, Urban K, Ulufatu S, Khawli LA, Prabhu S, Joseph S, Kelley RF. PMID: 26491012; PMCID: PMC4705991.
      View in: PubMed   Mentions: 45     Fields:    Translation:AnimalsCells
    14. A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components. J Control Release. 2015 Sep 28; 214:94-102. Kinnunen HM, Sharma V, Contreras-Rojas LR, Yu Y, Alleman C, Sreedhara A, Fischer S, Khawli L, Yohe ST, Bumbaca D, Patapoff TW, Daugherty AL, Mrsny RJ. PMID: 26210441.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    15. Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues. Mol Pharm. 2014 May 05; 11(5):1591-8. Boswell CA, Mundo EE, Ulufatu S, Bumbaca D, Cahaya HS, Majidy N, Van Hoy M, Schweiger MG, Fielder PJ, Prabhu S, Khawli LA. PMID: 24702191.
      View in: PubMed   Mentions: 30     Fields:    Translation:Animals
    16. Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor. MAbs. 2014 May-Jun; 6(3):689-96. Yip V, Palma E, Tesar DB, Mundo EE, Bumbaca D, Torres EK, Reyes NA, Shen BQ, Fielder PJ, Prabhu S, Khawli LA, Boswell CA. PMID: 24572100; PMCID: PMC4011913.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    17. Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice. MAbs. 2014; 6(6):1631-7. Kamath AV, Yip V, Gupta P, Boswell CA, Bumbaca D, Haughney P, Castro J, Tsai SP, Pacheco G, Ross S, Yan M, Damico-Beyer LA, Khawli L, Shen BQ. PMID: 25484068; PMCID: PMC4622559.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    18. Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies. J Med Chem. 2013 Dec 12; 56(23):9418-26. Boswell CA, Marik J, Elowson MJ, Reyes NA, Ulufatu S, Bumbaca D, Yip V, Mundo EE, Majidy N, Van Hoy M, Goriparthi SN, Trias A, Gill HS, Williams SP, Junutula JR, Fielder PJ, Khawli LA. PMID: 24131491.
      View in: PubMed   Mentions: 15     Fields:    Translation:Animals
    19. Cytoreductive chemotherapy improves the biodistribution of antibodies directed against tumor necrosis in murine solid tumor models. Mol Cancer Ther. 2013 Dec; 12(12):2827-36. Jang JK, Khawli LA, Park R, Wu BW, Li Z, Canter D, Conti PS, Epstein AL. PMID: 24130055; PMCID: PMC3929394.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    20. Drug delivery across the blood-brain barrier. Mol Pharm. 2013 May 06; 10(5):1471-2. Khawli LA, Prabhu S. PMID: 23641922.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    21. Vascular physiology and protein disposition in a preclinical model of neurodegeneration. Mol Pharm. 2013 May 06; 10(5):1514-21. Boswell CA, Mundo EE, Johnstone B, Ulufatu S, Schweiger MG, Bumbaca D, Fielder PJ, Prabhu S, Khawli LA. PMID: 23383983.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    22. An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2. Br J Pharmacol. 2013 Jan; 168(2):445-57. Boswell CA, Mundo EE, Firestein R, Zhang C, Mao W, Gill H, Young C, Ljumanovic N, Stainton S, Ulufatu S, Fourie A, Kozak KR, Fuji R, Polakis P, Khawli LA, Lin K. PMID: 22889168; PMCID: PMC3572570.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    23. Generation of tumor-targeted antibody-CpG conjugates. J Immunol Methods. 2013 Mar 29; 389(1-2):45-51. Li Z, Jang JK, Lechner MG, Hu P, Khawli L, Scannell CA, Epstein AL. PMID: 23279945.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    24. Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies. Pharm Res. 2013 Jan; 30(1):167-78. Yin S, Pastuskovas CV, Khawli LA, Stults JT. PMID: 22956170.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    25. Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med. 2012 Sep; 53(9):1454-61. Boswell CA, Mundo EE, Zhang C, Stainton SL, Yu SF, Lacap JA, Mao W, Kozak KR, Fourie A, Polakis P, Khawli LA, Lin K. PMID: 22872740.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    26. Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J. 2012 Sep; 14(3):612-8. Boswell CA, Bumbaca D, Fielder PJ, Khawli LA. PMID: 22648903; PMCID: PMC3385837.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimals
    27. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J. 2012 Sep; 14(3):554-8. Bumbaca D, Boswell CA, Fielder PJ, Khawli LA. PMID: 22610647; PMCID: PMC3385840.
      View in: PubMed   Mentions: 43     Fields:    Translation:Cells
    28. Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol. 2012 May; 166(1):368-77. Bumbaca D, Xiang H, Boswell CA, Port RE, Stainton SL, Mundo EE, Ulufatu S, Bagri A, Theil FP, Fielder PJ, Khawli LA, Shen BQ. PMID: 22074316; PMCID: PMC3415661.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    29. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem. 2012 Apr 26; 3(4):73-92. Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW. PMID: 22558487; PMCID: PMC3342576.
      View in: PubMed   Mentions: 76  
    30. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs. 2012 Mar-Apr; 4(2):243-55. Zheng Y, Tesar DB, Benincosa L, Birnböck H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, Fielder PJ, Grimm HP, Joshi A, Justies N, Kolaitis G, Lewin-Koh N, Li J, McVay S, O'Mahony J, Otteneder M, Pantze M, Putnam WS, Qiu ZJ, Ruppel J, Singer T, Stauch O, Theil FP, Visich J, Yang J, Ying Y, Khawli LA, Richter WF. PMID: 22453096; PMCID: PMC3361660.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimals
    31. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012 Jan 22; 30(2):184-9. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR. PMID: 22267010.
      View in: PubMed   Mentions: 278     Fields:    Translation:HumansAnimalsCells
    32. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther. 2012 Mar; 11(3):752-62. Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, Cain G, Van Hoy M, Majidy N, Bheddah S, dela Cruz Chuh J, Kozak KR, Lewin-Koh N, Nauka P, Bumbaca D, Sliwkowski M, Tibbitts J, Theil FP, Fielder PJ, Khawli LA, Boswell CA. PMID: 22222630.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    33. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem. 2011 Oct 19; 22(10):1994-2004. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, Fourie A, Chuh J, Koppada N, Saad O, Gill H, Shen BQ, Rubinfeld B, Tibbitts J, Kaur S, Theil FP, Fielder PJ, Khawli LA, Lin K. PMID: 21913715.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimals
    34. Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology. Ther Deliv. 2011 Jun; 2(6):769-91. Prabhu S, Boswell CA, Leipold D, Khawli LA, Li D, Lu D, Theil FP, Joshi A, Lum BL. PMID: 22822508.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    35. Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. PLoS One. 2011 Mar 15; 6(3):e17874. Boswell CA, Ferl GZ, Mundo EE, Bumbaca D, Schweiger MG, Theil FP, Fielder PJ, Khawli LA. PMID: 21436893; PMCID: PMC3060062.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    36. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010 Dec 15; 21(12):2153-63. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. PMID: 21053952.
      View in: PubMed   Mentions: 155     Fields:    Translation:HumansAnimalsCells
    37. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. MAbs. 2010 Nov-Dec; 2(6):613-24. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, Nijem I, Allison DE, Wong PY, Kao YH, Quan C, Joshi A, Harris RJ, Motchnik P. PMID: 20818176; PMCID: PMC3011216.
      View in: PubMed   Mentions: 110     Fields:    Translation:Animals
    38. Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125. Drug Metab Dispos. 2010 Dec; 38(12):2309-19. Pastuskovas CV, Mallet W, Clark S, Kenrick M, Majidy M, Schweiger M, Van Hoy M, Tsai SP, Bennett G, Shen BQ, Ross S, Fielder P, Khawli L, Tibbitts J. PMID: 20823292.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    39. Development and evaluation of a novel method for preclinical measurement of tissue vascular volume. Mol Pharm. 2010 Oct 04; 7(5):1848-57. Boswell CA, Ferl GZ, Mundo EE, Schweiger MG, Marik J, Reich MP, Theil FP, Fielder PJ, Khawli LA. PMID: 20704296.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    40. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J Immunother. 2008 Apr; 31(3):235-45. Sadun RE, Hsu WE, Zhang N, Nien YC, Bergfeld SA, Sabzevari H, Lutsiak ME, Khawli L, Hu P, Epstein AL. PMID: 18317364.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    41. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res. 2008 Jan 15; 14(2):579-88. Hu P, Arias RS, Sadun RE, Nien YC, Zhang N, Sabzevari H, Lutsiak ME, Khawli LA, Epstein AL. PMID: 18223234.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    42. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Handb Exp Pharmacol. 2008; (181):291-328. Khawli LA, Hu P, Epstein AL. PMID: 18071951.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    43. Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. Cancer Biother Radiopharm. 2007 Jun; 22(3):342-56. Zhang N, Khawli LA, Hu P, Epstein AL. PMID: 17651040.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    44. RA8, a human anti-CD25 antibody against human Treg cells. Hybridoma (Larchmt). 2007 Jun; 26(3):119-30. Arias RS, Flanagan ML, Miller KD, Nien YC, Hu P, Gray D, Khawli LA, Epstein AL. PMID: 17600493.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    45. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res. 2007 May 01; 13(9):2758-67. Zhang N, Sadun RE, Arias RS, Flanagan ML, Sachsman SM, Nien YC, Khawli LA, Hu P, Epstein AL. PMID: 17460060.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    46. Soluble Fc fusion proteins for biomedical research. Methods Mol Biol. 2007; 378:33-52. Flanagan ML, Arias RS, Hu P, Khawli LA, Epstein AL. PMID: 18605076.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCellsPHPublic Health
    47. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother. 2006 Jul-Aug; 29(4):425-35. Liu A, Hu P, Khawli LA, Epstein AL. PMID: 16799338.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    48. H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models. J Immunother. 2006 May-Jun; 29(3):274-83. Flanagan ML, Khawli LA, Hu P, Epstein AL. PMID: 16699370.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    49. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm. 2006 Feb; 21(1):5-14. Yu L, Ju DW, Chen W, Li T, Xu Z, Jiang C, Chen S, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL. PMID: 16480326.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    50. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res. 2005 Dec 01; 11(23):8492-502. Liu A, Hu P, Khawli LA, Epstein AL. PMID: 16322313.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    51. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res. 2005 Aug 15; 11(16):5971-80. Zhang N, Khawli LA, Hu P, Epstein AL. PMID: 16115941.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    52. NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):3084-93. Khawli LA, Hu P, Epstein AL. PMID: 15837764.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    53. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol. 2005 Mar 01; 23(7):1538-47. Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, Liao G, Chen Y, Fu Q, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL, Ju DW. PMID: 15735129.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    54. chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors. Hybrid Hybridomics. 2004 Feb; 23(1):1-10. Li J, Hu P, Khawli LA, Yun A, Epstein AL. PMID: 15000842.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    55. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res. 2003 Dec 01; 63(23):8384-92. Li J, Hu P, Khawli LA, Epstein AL. PMID: 14679000.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    56. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Cancer Biother Radiopharm. 2003 Dec; 18(6):931-40. Khawli LA, Alauddin MM, Hu P, Epstein AL. PMID: 14969605.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    57. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003 Aug 15; 63(16):5046-53. Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein AL. PMID: 12941833.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    58. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid Hybridomics. 2003 Aug; 22(4):197-207. Mizokami MM, Hu P, Khawli LA, Li J, Epstein AL. PMID: 14511565.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    59. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother. 2003 Jul-Aug; 26(4):320-31. Li J, Hu P, Khawli LA, Epstein AL. PMID: 12843794.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    60. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Cancer Biother Radiopharm. 2003 Jun; 18(3):339-53. Biela BH, Khawli LA, Hu P, Epstein AL. PMID: 12954121.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    61. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst. 2003 May 21; 95(10):741-9. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. PMID: 12759392.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    62. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood. 2003 Jun 15; 101(12):4853-61. Hu P, Mizokami M, Ruoff G, Khawli LA, Epstein AL. PMID: 12609842.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    63. Neotrofin increases heme oxygenase-1 selectively in neurons. Brain Res. 2003 Feb 07; 962(1-2):1-14. Wang X, Hauptmann N, Taylor E, Foreman M, Khawli LA, Maines MD. PMID: 12543450.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    64. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. Hybrid Hybridomics. 2003 Feb; 22(1):1-9. Khawli LA, Biela B, Hu P, Epstein AL. PMID: 12713684.
      View in: PubMed   Mentions: 11     Fields:    Translation:Animals
    65. Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins. Hybrid Hybridomics. 2002 Dec; 21(6):421-32. Sharifi J, Khawli LA, Hu P, Li J, Epstein AL. PMID: 12573106.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    66. Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells. Hybrid Hybridomics. 2002 Feb; 21(1):11-8. Khawli LA, Biela BH, Hu P, Epstein AL. PMID: 11991812.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    67. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. J Nucl Med. 2000 Feb; 41(2):355-62. Hornick JL, Sharifi J, Khawli LA, Hu P, Bai WG, Alauddin MM, Mizokami MM, Epstein AL. PMID: 10688122.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    68. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin Cancer Res. 1999 Jan; 5(1):51-60. Hornick JL, Khawli LA, Hu P, Sharifi J, Khanna C, Epstein AL. PMID: 9918202.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    69. Improving monoclonal antibody pharmacokinetics via chemical modification. Q J Nucl Med. 1998 Dec; 42(4):242-9. Sharifi J, Khawli LA, Hornick JL, Epstein AL. PMID: 9973839.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    70. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biother Radiopharm. 1998 Aug; 13(4):255-68. Hornick JL, Sharifi J, Khawli LA, Hu P, Biela BH, Mizokami MM, Yun A, Taylor CR, Epstein AL. PMID: 10850361.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    71. Antitumor effects of nonconjugated murine Lym-2 and human-mouse chimeric CLL-1 monoclonal antibodies against various human lymphoma cell lines in vitro and in vivo. Blood. 1997 Oct 15; 90(8):3160-6. Funakoshi S, Hirano A, Beckwith M, Asai O, Jorgensen G, Tian Z, Hornick JL, Hu P, Khawli LA, Epstein AL, Longo DL, Murphy WJ. PMID: 9376598.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    72. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood. 1997 Jun 15; 89(12):4437-47. Hornick JL, Khawli LA, Hu P, Lynch M, Anderson PM, Epstein AL. PMID: 9192768.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    73. Exploration of novel strategies to enhance monoclonal antibodies targeting. Q J Nucl Med. 1997 Mar; 41(1):25-35. Khawli LA, Epstein AL. PMID: 9195850.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    74. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res. 1996 Nov 01; 56(21):4998-5004. Hu P, Hornick JL, Glasky MS, Yun A, Milkie MN, Khawli LA, Anderson PM, Epstein AL. PMID: 8895756.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    75. Improved tumor localization and radioimaging with chemically modified monoclonal antibodies. Cancer Biother Radiopharm. 1996 Jun; 11(3):203-15. Khawli LA, Glasky MS, Alauddin MM, Epstein AL. PMID: 10851539.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    76. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2. Cancer Res. 1995 Jun 15; 55(12):2673-80. Epstein AL, Khawli LA, Hornick JL, Taylor CR. PMID: 7780984.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    77. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hum Antibodies Hybridomas. 1995; 6(2):57-67. Hu P, Glasky MS, Yun A, Alauddin MM, Hornick JL, Khawli LA, Epstein AL. PMID: 7492752.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    78. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer. 1994 Feb 01; 73(3 Suppl):824-31. Khawli LA, Miller GK, Epstein AL. PMID: 8306266.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    79. An improved method of direct labeling monoclonal antibodies with 99mTc. Int J Rad Appl Instrum B. 1992 May; 19(4):445-54. Alauddin MM, Khawli LA, Epstein AL. PMID: 1526809.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    80. N-(m-[125I]iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies. Int J Rad Appl Instrum B. 1992 Apr; 19(3):289-95. Khawli LA, van den Abbeele AD, Kassis AI. PMID: 1629018.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    81. m-[125I]iodoaniline: a useful reagent for radiolabeling biotin. Int J Rad Appl Instrum B. 1992 Apr; 19(3):297-301. Khawli LA, Kassis AI. PMID: 1629019.
      View in: PubMed   Mentions:    Fields:    
    82. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res. 1991 May 15; 51(10):2694-8. LeBerthon B, Khawli LA, Alauddin M, Miller GK, Charak BS, Mazumder A, Epstein AL. PMID: 2021947.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    83. Synthesis of 125I labeled N-succinimidyl p-iodobenzoate for use in radiolabeling antibodies. Int J Rad Appl Instrum B. 1989; 16(7):727-33. Khawli LA, Kassis AI. PMID: 2613529.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    84. Inhibition of herpesvirus and human DNA polymerases by alpha-halogenated phosphonoacetates. Biochem Pharmacol. 1987 Oct 01; 36(19):3103-6. McKenna CE, Khawli LA, Bapat A, Harutunian V, Cheng YC. PMID: 3663227.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    Leslie's Networks
    Concepts (375)
    Derived automatically from this person's publications.
    _
    Co-Authors (9)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _